Drug Resistance -- Cell Sensitivity Assays -- Cell Sensitivity Assays -- Cell Sensitivity Assays -- Analysis of Apoptosis in Tissue Sections -- Measurement of P-glycoprotein Function -- Measuring MDR-1 by Quantitative RT-PCR -- Microtiter Plate Technique for the Measurement of Glutathione in Fresh and Cryopreserved Lymphoblasts Using the Enzyme Recycling Method -- Measurement of Reduced Glutathione Using High-Pressure Liquid Chromatography -- Topoisomerase I and II Activity Assays -- 5-Fluorouracil Metabolizing Enzymes -- Measuring DNA Adducts by Immunoassay (ELISA) -- Measuring Drug-DNA Adducts in Individual Cells -- Measurement of Drug-Induced DNA Interstrand Crosslinking Using the Single-Cell Gel Electrophoresis (Comet) Assay -- PCR Analysis of Microsatellite Instability -- O 6-Alkylguanine-DNA Alkyltransferase Assay -- Analysis of the p53 Status of Tumors -- Bcl-2 Family Immunohistochemistry -- Genetic Analysis of Drug Resistance by Fluorescence In Situ Hybridization -- Genetic Analysis of Drug Resistance by Reverse In Situ Hybridization.

In Cytotoxic Drug Resistance Mechanisms, leading clinical and laboratory scientists describe cutting-edge methods for examining the mechanisms of cellular resistance to anticancer cytotoxics in human tumors. The protocols contain detailed instructions and extensive troubleshooting tips that allow researchers effectively to study a wide variety of drug resistance mechanisms, including aspects of drug-induced cell death, drug uptake/efflux, drug metabolism, and DNA repair. Each method is designed to help identify the correlation between molecular and biochemical data and the clinical responses of the patient. Cytotoxic Drug Resistance Mechanisms makes it possible to test established and laboratory-derived hypotheses with clinically derived tumor samples. State-of-the-art and readily reproducible, the methods presented here afford basic and clinical scientists a powerful complement of tools for investigating all the clinically relevant mechanisms used as markers of the biological response to anticancer chemotherapeutics today.